As the U.S. market navigates a complex landscape with the S&P 500 experiencing slight declines and Treasury yields on the rise, investors are closely monitoring legislative developments that could impact fiscal policy and economic growth. In this environment, high-growth tech stocks remain a focal point for those seeking potential opportunities in innovation-driven sectors, where adaptability and strong fundamentals can be key indicators of resilience amidst broader market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ Legend Biotech 26.73% 58.77% ★★★★★★ Travere Therapeutics 25.82% 65.45% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.65% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★

Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Amicus Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and delivery of novel medicines for rare diseases globally, with a market capitalization of approximately $1.98 billion.

Operations: Amicus Therapeutics focuses on the discovery, development, and commercialization of advanced therapies for rare diseases, generating revenue of $543.14 million.

Amicus Therapeutics has shown a notable reduction in its net loss from $48.42 million to $21.69 million year-over-year, signaling an improving financial trajectory. Despite recently lowering its 2025 revenue growth forecast from up to 24% to 22%, the company maintains a positive outlook for the second half of the year with expected GAAP net income. This optimism is further bolstered by a strategic licensing agreement with Dimerix Bioscience, enhancing Amicus's portfolio in treating Focal Segmental Glomerulosclerosis with potential annual revenue growth pegged at 17.7%. The deal not only diversifies Amicus's therapeutic offerings but also underscores its commitment to expanding its commercial footprint in high-stakes medical segments, setting a robust stage for future profitability and market presence.

Dive into the specifics of Amicus Therapeutics here with our thorough health report. Understand Amicus Therapeutics' track record by examining our Past report.NasdaqGM:FOLD Revenue and Expenses Breakdown as at May 2025

Blueprint Medicines

Simply Wall St Growth Rating: ★★★★★★

Story Continues

Overview: Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, with a market cap of approximately $6.54 billion.

Operations: Blueprint Medicines generates revenue primarily from its pharmaceuticals segment, amounting to $562.12 million. The company focuses on creating therapies for specific cancer types and blood disorders, operating both in the United States and internationally.

Blueprint Medicines, amid a competitive biotech landscape, is steering towards profitability with its innovative treatments. The company's recent earnings reveal a significant revenue jump to $149.41 million from $96.12 million year-over-year, showcasing a robust annualized revenue growth of 21.4%. This surge is underpinned by strategic advancements like the increased 2025 revenue guidance for AYVAKIT net product revenues, projected between $700 million to $720 million. Moreover, Blueprint’s commitment to R&D is evident as it continues to innovate in treating mast cell-driven diseases and other complex conditions, ensuring it remains at the forefront of biotechnological breakthroughs and patient care advancements.

Click to explore a detailed breakdown of our findings in Blueprint Medicines' health report. Gain insights into Blueprint Medicines' past trends and performance with our Past report.NasdaqGS:BPMC Revenue and Expenses Breakdown as at May 2025

Ultragenyx Pharmaceutical

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing and commercializing novel treatments for rare and ultra-rare genetic diseases across multiple regions worldwide, with a market cap of $3.42 billion.

Operations: Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of treatments for rare genetic diseases across various global regions. The company's revenue primarily stems from its novel product offerings in this niche market, amounting to $590.69 million.

Ultragenyx Pharmaceutical, amid its recent endeavors, reaffirmed its 2025 revenue guidance between $640 million to $670 million, reflecting a robust commitment to growth. This projection is supported by a notable first-quarter revenue increase to $139.29 million from the previous year's $108.83 million. The company's R&D dedication is also evident, focusing on advanced genetic and cell therapies as showcased in numerous industry conferences including the Pharma Manufacturing World Summit and ASGCT Annual Meeting. These strategic moves highlight Ultragenyx’s pivotal role in pioneering treatments within the biotech sector, despite a current net loss which narrowed to $151.08 million from last year’s $170.68 million, setting a potentially brighter future trajectory.

Click here to discover the nuances of Ultragenyx Pharmaceutical with our detailed analytical health report. Review our historical performance report to gain insights into Ultragenyx Pharmaceutical's's past performance.NasdaqGS:RARE Earnings and Revenue Growth as at May 2025

Where To Now?

Discover the full array of 234 US High Growth Tech and AI Stocks right here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:FOLDNasdaqGS:BPMC and NasdaqGS:RARE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments